The market share information in this press release is partly derived from our own independent research. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.
Advanced Cell Technology, Inc. On October 30,Terumo applied to Japan's Ministry of Health, Labour and Welfare for approval to produce and market its skeletal myoblast sheets as a regenerative medicinal therapy for treating severe heart failure caused by chronic ischemic heart disease.
The Phase I trials were conducted on a myoblast stem cell therapy involving transplantation of expanded autogolous myoblast adult progenitor stem cells derived from a small biopsy of skeletal muscle in the leg.
The Company is in the process of evaluating the data and is working with its scientists to evaluate the size and score of a potential Phase II trial. Terumo has also participated in a research project on regenerative medicine using cell sheets.
According to the National Institute of Health, approximately five million people suffer from congestive heart failure, with an estimatednew cases diagnosed each year.